Burnett, A., Cavenagh, J., Russell, N., Hills, R., Kell, J., Jones, G., . . . Clark, R. (2016). Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: A comparison of 3 mg/m(2) with 6 mg/m(2) in the NCRI AML17 Trial. Haematologica.
Style de citation ChicagoBurnett, Alan, et al. "Defining the Dose of Gemtuzumab Ozogamicin in Combination With induction Chemotherapy in Acute Myeloid Leukemia: A Comparison of 3 mg/m(2) With 6 Mg/m(2) in the NCRI AML17 Trial." Haematologica 2016.
Style de citation MLABurnett, Alan, et al. "Defining the Dose of Gemtuzumab Ozogamicin in Combination With induction Chemotherapy in Acute Myeloid Leukemia: A Comparison of 3 mg/m(2) With 6 Mg/m(2) in the NCRI AML17 Trial." Haematologica 2016.